ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 102 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.45 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $276,343 | -47.0% | 52,042 | -4.9% | 0.00% | -100.0% |
| Q2 2023 | $521,434 | -10.4% | 54,715 | +3.4% | 0.00% | 0.0% |
| Q1 2023 | $581,878 | -26.1% | 52,898 | -0.5% | 0.00% | 0.0% |
| Q4 2022 | $786,886 | -20.3% | 53,168 | +3.0% | 0.00% | -50.0% |
| Q3 2022 | $987,000 | +13.8% | 51,625 | +26.9% | 0.00% | +100.0% |
| Q2 2022 | $867,000 | +34.2% | 40,693 | +21.4% | 0.00% | 0.0% |
| Q1 2022 | $646,000 | -14.1% | 33,524 | -7.6% | 0.00% | 0.0% |
| Q4 2021 | $752,000 | -11.3% | 36,263 | +2.1% | 0.00% | 0.0% |
| Q3 2021 | $848,000 | -18.5% | 35,513 | -6.9% | 0.00% | 0.0% |
| Q2 2021 | $1,041,000 | +3.2% | 38,143 | +9.4% | 0.00% | 0.0% |
| Q1 2021 | $1,009,000 | +14.5% | 34,863 | +11.3% | 0.00% | 0.0% |
| Q4 2020 | $881,000 | +9.9% | 31,322 | +14.5% | 0.00% | 0.0% |
| Q3 2020 | $802,000 | +85.6% | 27,357 | +91.4% | 0.00% | 0.0% |
| Q2 2020 | $432,000 | -8.3% | 14,291 | -9.6% | 0.00% | 0.0% |
| Q1 2020 | $471,000 | – | 15,811 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |